**Core Concept**
The patient's presentation with a combination of cytopenias, blast cells in the peripheral blood, and specific cytogenetic abnormalities is characteristic of a myeloid neoplasm. In this case, the presence of 14% blasts, increased neutrophils, and dysplasia in the myeloid lineage cells points towards a diagnosis of Acute Myeloid Leukemia (AML).

**Why the Correct Answer is Right**
The patient's cytogenetic study revealed a t(8;21) translocation, which is a common genetic abnormality in AML. This translocation involves the RUNX1 gene on chromosome 21 and the ETO gene on chromosome 8, leading to the formation of a fusion protein that disrupts normal hematopoiesis. The presence of 14% blasts in the peripheral blood is also consistent with AML, as this is a hallmark of the disease. Additionally, the patient's low platelet count and decreased hemoglobin levels are indicative of bone marrow failure, which is a common feature of AML.

**Why Each Wrong Option is Incorrect**

**Option B:** CML is characterized by a chronic phase with increased mature neutrophils and basophils, and a specific chromosomal abnormality, the Philadelphia chromosome (t(9;22)). This patient's presentation does not match CML.

**Option C:** MDS (Myelodysplastic Syndrome) is a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis and a high risk of progression to AML. However, the presence of 14% blasts in the peripheral blood is higher than typically seen in MDS, making AML a more likely diagnosis.

**Option D:** ALL (Acute Lymphoblastic Leukemia) is characterized by the presence of lymphoblasts in the peripheral blood, which are not seen in this patient's peripheral smear.

**Clinical Pearl / High-Yield Fact**
The t(8;21) translocation is a common genetic abnormality in AML, and its presence should raise suspicion for this diagnosis. It is essential to perform cytogenetic studies in patients with suspected AML to identify specific genetic abnormalities that can guide treatment decisions.

**✓ Correct Answer: A. AML**